Allon Therapeutics Inc.

Allon Therapeutics Inc.

November 28, 2011 08:30 ET

Allon Invited to Present at Two Major Conferences

VANCOUVER, BRITISH COLUMBIA--(Marketwire - Nov. 28, 2011) - Allon Therapeutics Inc. (TSX:NPC) President and CEO Gordon McCauley has been invited to present an update of the Company's business progress on Tuesday, November 29, 2011 at the Piper Jaffray Health Care Conference in New York City. McCauley's presentation will include an update of the Company's programs, including its fully enrolled pivotal clinical trial evaluating lead neuroprotective drug candidate, davunetide, as a potential treatment for progressive supranuclear palsy (PSP), a rapidly progressing and fatal degenerative brain disease.

The live webcast may be viewed at 5:30 a.m. PST (8:30 a.m. EST) at

The presentation will be immediately archived and available for viewing for three months from the Company's website at

Piper Jaffray is a leading middle-market investment bank and asset management firm, serving clients in the U.S. and internationally, combining deep product and sector expertise with ready access to global capital. Founded in 1895, the firm has offices across the United States, Hong Kong, London and Zurich.

In addition, Allon has been invited to participate this week at the prestigious Windhover's Therapeutics Area Partnerships conference. Allon has been selected by an expert panel as one of the "Top 10" not yet partnered neuroscience programs in the world. The conference is one of the industry's most targeted partnering meetings in the therapeutic area, and will be held at the Westin Copley Place in Boston, Massachusetts from November 30th to December 2nd 2011. Participation at the conference is by invitation only. Allon's Vice President of Clinical Development and Chief Medical Officer, Dr. Michael Gold, will present an overview of Allon's neuroprotective platform technology at 8:10 a.m. PST (11:10 a.m. EST) on December 1st, 2011.

About Allon

Allon Therapeutics Inc. is a clinical-stage biotechnology company focused on bringing to market innovative central nervous system therapies. Allon's lead drug davunetide is proceeding in a pivotal Phase 2/3 clinical trial in an orphan indication, progressive supranuclear palsy (PSP), under a Special Protocol Assessment (SPA) with the U.S. Food and Drug Administration (FDA). This pivotal trial is based upon statistically significant human efficacy demonstrated in patients with amnestic mild cognitive impairment (a precursor to Alzheimer's disease) and cognitive impairment associated with schizophrenia, and in positive biomarker data.

The Company is listed on the Toronto Stock Exchange under the trading symbol "NPC".

Forward Looking Statements

Statements contained herein, other than those which are strictly statements of historical fact may include forward-looking information. Such statements will typically contain words such as "believes", "may", "plans", "will", "estimate", "continue", "anticipates", "intends", "expects", and similar expressions. While forward-looking statements represent management's outlook based on assumptions that management believes are reasonable, forward-looking statements by their nature are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by them. Such factors include, among others, the inherent uncertainty involved in scientific research and drug development, Allon's early stage of development, lack of product revenues, its additional capital requirements, the risks associated with successful completion of clinical trials and the long lead-times and high costs associated with obtaining regulatory approval to market any product which Allon may eventually develop. Other risk factors include the limited protections afforded by intellectual property rights, rapid technology and product obsolescence in a highly competitive environment and Allon's dependence on collaborative partners and contract research organizations. These factors can be reviewed in Allon's public filings at and should be considered carefully. Readers are cautioned not to place undue reliance on such forward-looking statements. Similarly, nothing in this press release is meant to promote a pharmaceutical product or make a regulated claim of efficacy.

Contact Information